Leading Hub Services Provider COPILOT Appoints Valerie Sullivan as Chief Commercial Officer
19 déc. 2023 11h35 HE
|
COPILOT Provider Support Services
LEADING HUB SERVICES PROVIDER COPILOT APPOINTS VALERIE SULLIVAN AS CHIEF COMMERCIAL OFFICER
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca
19 déc. 2023 10h00 HE
|
Related Sciences
Former CEOs and executives from Genentech, Novartis, Seagen, Pfizer, and Celgene join drug AI/ML drug discovery firm Related Sciences as senior advisors.
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innovation Fund and ARTIS Ventures
19 déc. 2023 09h00 HE
|
Unnatural Products
Santa Cruz, CA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech company pairing AI with chemistry to usher in the next generation of molecularly targeted therapeutics,...
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
19 déc. 2023 08h00 HE
|
23andMe, Inc.
Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1 A second potentially...
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens
18 déc. 2023 07h00 HE
|
Replay Bio
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens Replay and its...
Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®
18 déc. 2023 07h00 HE
|
Replay Bio
Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy® Syena...
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
18 déc. 2023 06h00 HE
|
First Wave BioPharma, Inc.
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent...
Actuators and Valves Market Size to Exceed USD 615.6 million By 2031, with a Robust CAGR of 4.3%| States Transparency Market Research, Inc.
15 déc. 2023 04h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The actuators and valves market was worth US$ 415.3 million in 2022. A CAGR of 4.3% is...
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
07 déc. 2023 12h01 HE
|
Spherix Global Insights
Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call,...
Yseop Announces Strategic Investment and Celebrates Milestone of 150 Clinical Trials Powered by Generative AI
07 déc. 2023 09h00 HE
|
Yseop
NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Yseop, a world-leading Generative AI company for life sciences, today announces the closing of a strategic investment round, with new investor Novartis...